(Q45970215)

18 December 2017

title

TL-118-anti-angiogenic treatment in pancreatic cancer: a case report. (English)

1 reference

18 December 2017

main subject

angiogenesis inhibitor

1 reference

1 reference

Shani Breuer

1

1 reference

18 December 2017

Ofra Maimon

2

1 reference

18 December 2017

Liat Appelbaum

3

1 reference

18 December 2017

Tamar Peretz

4

1 reference

18 December 2017

Ayala Hubert

5

1 reference

18 December 2017

publication date

23 April 2013

1 reference

18 December 2017

published in

Medical Oncology

1 reference

18 December 2017

volume

30

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

585

1 reference

18 December 2017

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

1 reference

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

Angiogenesis and hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

Does cimetidine improve prospects for cancer patients?. A reappraisal of the evidence to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

Cimetidine inhibits angiogenesis and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

Diclofenac Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer by Modulation of VEGF Levels and Arginase Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0585-9

Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23609193

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23609193

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-013-0585-9

1 reference

18 December 2017

Dimensions Publication ID

1015055656

0 references

1 reference

18 December 2017